Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
Phase 1 Unknown
75 enrolled
WinPro
Phase 2 Unknown
200 enrolled
PREDICTAM
Phase 4 Unknown
100 enrolled
HOT
Phase 3 Unknown
1,884 enrolled
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Unknown
700 enrolled
NEMO
Unknown
300 enrolled
HOBOE
Phase 3 Unknown
1,294 enrolled
ASPAIT
Phase 3 Unknown
680 enrolled
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Phase 2 Unknown
46 enrolled
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Phase NA Unknown
150 enrolled
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Phase 2 Unknown
40 enrolled
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Phase 3 Unknown
160 enrolled
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Unknown
1,000 enrolled
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
Unknown
1,354 enrolled
NUTRIBREAST
Unknown
300 enrolled
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
Phase 3 Unknown
412 enrolled
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Phase 3 Unknown
3,697 enrolled
Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device
Unknown
20 enrolled
MEGA
Phase 2 Unknown
20 enrolled
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Phase 3 Unknown
810 enrolled
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Phase 2 Unknown
185 enrolled
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
Unknown
100 enrolled
Breast Cancer Treatment Based on Organ-like Culture
Unknown
300 enrolled
Pembro
Phase 2 Unknown
25 enrolled
STEP
Phase 3 Unknown
300 enrolled
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Phase 3 Unknown
844 enrolled
OTT 17-01
Phase 2 Unknown
82 enrolled
Tamoxifen in Patients With Oesophageal Cancer
Phase 1 Unknown
20 enrolled
Cimicifuga
Phase 4 Unknown
60 enrolled
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Phase 3 Unknown
600 enrolled
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Phase NA Unknown
600 enrolled
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
Phase NA Unknown
360 enrolled
TGOG1005
Phase 2 Unknown
44 enrolled
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Phase 2/3 Unknown
3,036 enrolled
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Phase 2 Unknown
50 enrolled
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Phase 2 Unknown
200 enrolled
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
Phase 2 Unknown
80 enrolled
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
Phase 3 Unknown
4,400 enrolled
Tamoxifen in Treating Women With Breast Cancer
Phase 3 Unknown
20,000 enrolled
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Unknown
350 enrolled
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
Phase 3 Unknown
300 enrolled
NEST
Phase 3 Unknown
290 enrolled
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
Phase 2 Unknown
200 enrolled
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
Phase 3 Unknown
Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
Phase 2 Unknown
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
Phase NA Unknown
2,000 enrolled
CONSET
Phase 3 Unknown
260 enrolled
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Unknown
94 enrolled